



IFW

**MAIL STOP AMENDMENT**  
Attorney Docket No. 27632U

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

**FLOCKERZI**

Confirmation No.: 6862

Serial No: 10/591,955

Group Art Unit: 1617

Filed: September 8, 2006

Examiner: MANOHAR, M.

For: **NOVEL N-(ALKOXYALKYL) CARBAMOYL-SUBSTITUTED 6-PHENYL-BENZONAPHTHYRIDINE DERIVATIVES AND THEIR USE AS PDE 3/4 INHIBITORS**

**TRANSMITTAL LETTER**

Commissioner for Patents  
Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Transmittal Letter; and
- (2) Response to Restriction/Election Requirement.


The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account Number 14-0112.

Respectfully submitted,

**THE NATH LAW GROUP**

Date: January 21, 2009  
**THE NATH LAW GROUP**  
112 S. West Street  
Alexandria, VA 22314

Tel: (703) 548-6284  
Fax: (703) 683-8396

  
\_\_\_\_\_  
Gary M. Nath  
Reg. No. 26,965  
Sheldon M. McGee  
Reg. No. 50,454  
Customer No. 34375



**MAIL STOP AMENDMENT**  
Attorney Docket No. 27632U

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

FLOCKERZI

Confirmation No.: 6862

Serial No: 10/591,955

Group Art Unit: 1617

Filed: September 8, 2006

Examiner: MANOHAR, M.

For: **NOVEL N-(ALKOXYALKYL) CARBAMOYL-SUBSTITUTED 6-PHENYL-BENZONAPHTHYRIDINE DERIVATIVES AND THEIR USE AS PDE 3/4 INHIBITORS**

**RESPONSE TO RESTRICTION REQUIREMENT**

MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This paper is submitted responsive to the Official Action dated December 24, 2008, making a Response due on or before January 24, 2009. As January 24, 2009 is a Saturday, pursuant to **MPEP § 710.01(a)**, this reply is timely if it is filed on the next succeeding business day. As such, this Response is timely filed.

**REMARKS**

Claims 1-6, 8, 10 and 11 are pending in the captioned application. The Examiner required restriction under 35 U.S.C. §§ 121 and 372, as follows:

Group I: Claims 1-6 and 8, drawn to compounds of formula 1.

Group II: Claims 10-11, drawn to a method of treating illness in a patient by administering a compound of formula 1.